Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.81 |
| ▸ | ESR1 | P03372 | 14/20 | 0.81 |
| ▸ | ESRRA | P11474 | 10/20 | 0.71 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592071 | 0.90 | ESR2 (1.00) | ESR2ESR1ESRRACAPN1 | |
| SCHEMBL13948737 | 0.88 | ESR2 (0.79) | ESR2ESR1ESRRA | |
| SCHEMBL13087050 | 0.88 | ESR2 (0.79) | ESR2ESR1ESRRA | |
| SCHEMBL18381906 | 0.86 | ESR2 (0.79) | ESR2ESR1ESRRA | |
| SCHEMBL2588634 | 0.85 | ESR2 (0.74) | ESR2ESR1ESRRA | |
| SCHEMBL18381907 | 0.84 | ESR1 (0.58) | ESR2ESR1ESRRACAPN1CTSL | |
| SCHEMBL2586208 | 0.83 | ESR2 (1.00) | ESR2ESR1ESRRA | |
| SCHEMBL27769678 | 0.83 | ESR2 (0.65) | ESR2ESR1ESRRA | |
| SCHEMBL14138429 | 0.81 | ESR2 (0.75) | ESR2ESR1ESRRA | |
| SCHEMBL13087005 | 0.81 | ESR2 (0.70) | ESR2ESR1ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | claimed |
| EP-2647376-A1 | Nuclear receptor binding agents | Gtx, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2106212-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, Inc. (US) | 2009-10-07 | — | — | EP | claimed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | claimed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | disclosed |
| CN-102970870-A | Nuclear receptor binding agents | GTX INC | 2013-03-13 | — | — | CN | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| CN-101641013-A | Nuclear receptor binding agents | GTX INC US | 2010-02-03 | — | — | CN | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | ESR2 4/4885ESR1 28/4885ESRRA 3/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | ESR2 22/4885ESR1 63/4885ESRRA 4/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | ESR2 16/4885ESR1 145/4885ESRRA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.